Seventh Sense Biosystems, Inc., a Cambridge, MA-based developer of virtually painless blood collection and diagnostic platforms, raised $16m in Series B financing.
Backers included new investors the Venture Capital unit of Siemens Financial Services (SFS VC), Novartis and Laboratory Corporation of America® Holdings (LabCorp®) and existing investors Flagship Ventures and Polaris Partners.
The company intends to use the funds to complete the development of its platform.
Founded in 2008, within Flagship VentureLabs™ and led by Howard Weisman, Chief Executive Officer, 7SBio is developing and commercializing an array of products based on its proprietary Touch Activated Phlebotomy (TAP™) painless blood collection platform, with an initial focus on enabling diagnostic testing at the point of care by reducing the discomfort, anxiety and hassle of blood sample collection.
FinSMEs
13/08/2014